Get this delivered to your inbox, and more info about our products and services.
Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment
Stifel sees Biogen stock rallying nearly 32% from here.
14 words~1 min read
Related reading
Stifel Nicolaus Remains a Buy on Biogen (BIIB)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen today and set a price target of $242.00.Claim 55% Off…
This biotech stock could see a sharp swing higher after years of struggling,…
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Biogen…
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and…
Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease…
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.
Goldman Sachs says this under-the-radar biotech play could more than double in…
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.